Glimisave M2 850 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 850 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, enhances pancreatic insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The extended-release formulation of Glimisave M2 850 allows for sustained drug release, promoting improved patient compliance through reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination therapy is particularly beneficial for patients inadequately controlled on monotherapy or lifestyle interventions alone. It is essential to use Glimisave M2 850 alongside diet and exercise to achieve optimal glycemic control. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia is recommended. Glimisave M2 850 offers a synergistic approach to managing hyperglycemia, improving metabolic parameters, and reducing the risk of diabetes-related complications. It should be prescribed under medical supervision with individualized dose adjustments based on therapeutic response and tolerability.